{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"SEGYOKHGGFKMCX-UHFFFAOYSA-N","prefName":"JZL184","symbol":"JZL184","iupacName":null,"aliases":["JZL-184"],"cas":"1101854-58-3","pubchemCid":"25021165","chebiId":null,"smiles":"C1CN(CCC1C(C2=CC3=C(C=C2)OCO3)(C4=CC5=C(C=C4)OCO5)O)C(=O)OC6=CC=C(C=C6)[N+](=O)[O-]","molecularFormula":"C27H24N2O9","molecularWeight":520.5,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/25021165"}},"classification":{"family":"ecs_tool","familyLabel":"Modulateur ECS (recherche)","origin":"synthetic","originLabel":"Synthétique","structuralClassFr":null},"originSynthesis":{"heading":"Origine (outil de recherche)","summaryFr":"Inhibiteur covalent sélectif de la MAGL ; obtenu par synthèse organique (carbamylation du résidu Ser122 catalytique)","originNote":"Recherche pharmaceutique (Cravatt)","discovered":"2009"},"pharmacology":{"summaryFr":"JZL184 est l'inhibiteur de MAGL de référence - décrit par Long, Li et Cravatt (Nat Chem Biol 2009, PMID 19029916) au Scripps Research Institute. Mécanisme covalent irréversible (Ser122). Élévation chronique de 2-AG cérébral conduit à une désensibilisation CB1 (down-regulation) qui complique l'usage chronique : la stratégie clinique privilégie aujourd'hui les inhibiteurs MAGL réversibles (ABX-1431 / lu AG06466) ou plus sélectifs (MJN110, KML29).","receptorSummaryFr":"Inhibiteur MAGL (IC50 ≈ 8 nM hMAGL) - élève le 2-AG cérébral d'un facteur ≈ 10× sans toucher significativement la FAAH","binding":[{"target":"MAGL","efficacy":"antagonist","relativeActivity":95,"reported":"IC50 ≈ 8 nM (hMAGL)","confidence":"medium"},{"target":"CB1","efficacy":"modulator","relativeActivity":10,"reported":"indirect via 2-AG","confidence":"medium"}],"references":[{"label":"Long · Nat Chem Biol 2009","pmid":"19029916","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/19029916/"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Apaisement","description":"Détente du corps et de l'esprit ; baisse du bruit mental sans somnolence marquée.","intensity":70},{"key":"focus","label":"Clarté","description":"Attention soutenue et pensée claire ; lucidité fonctionnelle, pas d'euphorie.","intensity":50},{"key":"sleep","label":"Sommeil","description":"Effet sédatif : aide à l'endormissement et à la continuité du sommeil profond.","intensity":55},{"key":"appetite","label":"Appétit","description":"Stimulation de la faim et de l'appréciation gustative (effet « munchies »).","intensity":60},{"key":"uplift","label":"High","description":"Euphorie et intensité sensorielle ; perception du temps et de l'espace modifiée.","intensity":55}],"doseRanges":null,"humanDataCharacterised":true},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":false,"bannerTextFr":null,"toxicologyFr":null},"legal":{"scheduleStatus":"unscheduled","scheduleLabel":"Non listé","frScheduleStatus":null,"tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":"Non listé","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"Non listé, outil de recherche","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"Non listé, outil de recherche","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Long · Nat Chem Biol 2009","pmid":"19029916","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/19029916/"}],"meta":{"slug":"jzl184","url":"https://phytogrammes.com/wiki/jzl184","lastVerified":"2026-05-01","dataUpdatedAt":"2026-05-01","confidence":"medium","dataCompletenessPct":80,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}